**Lay Description of Important Outcomes**

We have determined that 5-day on 2-day off metronomic low dose PARPi talazoparib plus temozolomide treatment for one month does not cause substantial weight loss. The high dose treatment used previously caused substantial weight loss. As such, we conclude that the low dose treatment is superior in control animals because it causes no weight loss and adverse blood outcomes. The clinical relevance of this low dose treatment is that is causes no notable side-effects and is therefore best for control study animals. If the metronomic low dose treatment also reduces metastasis then such treatment protocols will improve the potential for positive health outcomes. We expect this will translate to increased the lifespan of the animals with implanted metastatic breast cancers. Experiments are in progress to determine if the low dose treatment will reduce tumor volume, and circulating tumor cells. In the upcoming year will carry out experiments to determine if this metronomic low dose therapy extends the lifespan of the animals in the study.